A New Way to Increase Confidence in Identifying Patients Likely to Have Multiple Sclerosis
Diagnosing Multiple Sclerosis (MS) can be very difficult and time consuming, sometimes taking months to years of repeated testing and watchful waiting. Advances in the field have allowed this process to be significantly shortened, lessening the medical resource expenditure and the consequences of uncertainty on peace of mind.
Initially, physicians need to exclude other diseases that may have similar presentations, both in terms of symptoms and the ambiguity of some of our attempts at confirmatory testing. Symptoms can be non-specific, and our various test results, including MRI, can lack accuracy.
Confidence is critical in making a diagnosis of the import represented by MS. There has been an unmet need for patients and physicians to identify those with a high probability of having MS, but who are not yet fulfilling the recommended criteria. Glycominds has introduced the gMS®Dx test, a new blood test for MS biomarkers. This revolutionary test helps physicians identify which patients - among those having had a first neurological event with a positive MRI - are more likely to develop MS.
Numerous studies show the gMS®Dx test delivers consistent, reproducible and accurate results. The gMS®Dx test provides clinically valuable information clinicians can use to help make decisions about the likelihood of having Multiple Sclerosis, based on approximately 1,500 patients studied to date. The gMS®Dx test confirms your diagnosis opinions and gives patients more confidence in their decisions regarding treatment.
NEW - First blood-based biomarker test validated for MS
POWERFUL - High positive predictive value for identifying patients likely to have MS after the first neurological event
The gMS®Dx test differentiates MS from other neurological diseases
SIMPLE - Easy, non-invasive test, that complements MRI
gMS® is a registered trademark of Glycominds. Patent US 7,537,900